NATIONAL CANCER CENTER
Fruquintinib-Capecitabine Combination Shows Promise as Maintenance Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer
Phase 1/2 study data presented at the 2025 AACR Annual Meeting revealed promising efficacy of fruquintinib plus capecitabine as maintenance therapy in RAS/BRAF wild-type metastatic colorectal cancer patients.
Afinitor Plus Somatuline Significantly Prolongs Survival in GEP-NETs
Combination therapy with Afinitor and Somatuline demonstrates a significant improvement in progression-free survival (PFS) compared to Afinitor alone in patients with unresectable or recurrent GEP-NETs.
Everolimus Plus Lanreotide Significantly Extends PFS in GEP-NETs
The combination of everolimus and lanreotide significantly prolonged progression-free survival (PFS) compared to everolimus alone in GEP-NETs.
Disitamab Vedotin Shows Promising Activity in HER2-Expressing Metastatic Breast Cancer with PAM Pathway Abnormalities
Disitamab vedotin (RC48) demonstrates an objective response rate of 34.4% in HER2-expressing metastatic breast cancer patients with abnormal PAM pathway activation.
Japan's National Cancer Center Launches Nationwide Clinical Trial Network with Paradigm Health
The National Cancer Center (NCC) in Japan has launched LC-SCRUM-CD, a nationwide clinical trial network for precision medicine in cancer treatment.
Eisai's E7820 Shows Promise in Shrinking Tumors with HRR Deficiency
Eisai's E7820 demonstrated tumor shrinkage in patient-derived xenograft models of bile duct and uterine cancers, suggesting potential efficacy in these tumor types.